RV: Some of that reversal, if we think back over this year, is when DeepSeek announced how strong and how efficient and effective its model was. That news was certainly a shot across the bow of US-based hyperscalers, but I think it also highlights that there is innovation beyond the US.
Even within AI, when we think about who makes all of NVIDIA’s chips, TSMC makes all of them. And what equipment do they use to make it? It’s all from ASML and their extreme ultraviolet lithography (EUV) equipment. Both are near monopolies from a Taiwanese company and a Dutch company. Even the inputs are less well known, like a company called Disco in Japan: They slice, dice, and polish the wafers that are used in making those chips, and have something like a 70% market share. This is a critical niche component to the whole infrastructure and AI supply chain. Again, these are non-US companies.
When we think about who makes all of NVIDIA’s chips, TSMC makes all of them. And what equipment do they use to make it? It’s all from ASML and their extreme ultraviolet lithography (EUV) equipment. Both are near monopolies from a Taiwanese company and a Dutch company.
Even outside of tech, you’ve got a company like Schneider Electric based in France. They do energy management equipment and services and software around that. People thought about it for green energy, but the reality is they’ve got a fantastic and fast-growing business helping build out AI infrastructure. Those AI data centers need very efficient and consistent power, and I think it’s grown to something like 20% of their business from almost nothing not too many years ago.
Health care is another area of innovation outside of the US. Anti-obesity, weight loss drugs have certainly been a focus of markets and the Health Care sector. Novo Nordisk, the Danish company, is the leader. They’re competing today with Lilly. When we look forward, what people are looking for is not just the weight loss but convenience and a better safety profile with fewer side effects.
Lilly has taken to phase three a once daily oral GLP-1 drug. That would certainly be more convenient. But interestingly, the science behind that is from Chugai, a Japanese-based company. And when we think about lower side effects, Roche recently did a deal to co-develop drugs with Zealand, a Danish-based company. It’s still an injectable, but far fewer side effects than Ozempic, Wegovy, and Mounjaro. Again, a lot of innovation for future growth is coming from non-US Health Care companies.
AS: That’s a really good point. When you look at the top 20 cash-flow return-on-investment businesses, you mentioned areas of innovation like Health Care, Information Technology, and Industrials, but there are other sectors as well. You do see a preponderance of high-quality, growing businesses in those sectors outside the US.
If you look at the ACWI benchmark, the US has a large weight, 67% in US and 33% in International. But when you slice it by market cap and look at the number companies greater than US$5 billion in that high-quality growth universe, it’s a very different skew: 73% of the companies in that high-quality growth universe are outside the US. Certainly the monopoly on innovation does not belong to the United States.